表紙
市場調查報告書
商品編碼
974788

血漿蛋白分解酵素C1抑制劑治療市場:各藥物類型,各用量,各流通管道,各地區:規模,佔有率,預測,及機會分析(2020年∼2027年)

Plasma Protease C1-inhibitor Treatment Market, by Drug Type, by Dosage, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日期: | 出版商: Coherent Market Insights | 英文 186 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

C1-抑制劑(C1-H),屬於絲胺酸蛋白分解酵素抑制劑的超級家族。 C1抑制劑控制C1複合體的活性化。C1r或C1s蛋白分解酵素和蛋白質形成分解惰性的化學數量論的複合體。還有在調節重要的生理途徑(包括補體活性化,凝血,纖溶和激肽的生成)中,也起著重要作用。 它是FXIIa因子的最有效抑製劑,還抑制胰凝乳蛋白酶和激肽釋放酶。

本報告提供血漿蛋白分解酵素C1抑制劑治療市場相關調查,市場概要,以及各藥物類型,各用量,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告的說明
  • 市場定義和範圍
  • 摘要整理
  • 市場明細:各藥物類型
  • 市場明細:各用量
  • 市場明細:各流通管道
  • 市場明細:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
  • 促進因素
  • 阻礙因素
  • 影響分析
  • 市場機會
  • 合作與收購

第4章 血漿蛋白分解酵素C1抑制劑治療市場-COVID-19大流行的影響

  • COVID-19後的影響
  • COVID-19對研究開發活動的影響
  • 需求與供給分析
  • 對製造業的整體影響

第5章 血漿蛋白分解酵素C1抑制劑治療市場:各藥物類型,2016年∼2027年(百萬美元)

  • 簡介
  • 市場佔有率分析,2020年及2027年(%)
  • 與前一年同期比較成長分析,2017-2027
  • 市場區隔趨勢
    • C1抑制劑
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)
    • 激肽釋放酶抑製劑
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)
    • 選擇性緩激肽B2受體拮抗劑
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)

第6章 血漿蛋白分解酵素C1抑制劑治療市場:各用量,2016年∼2027年(百萬美元)

  • 簡介
  • 市場佔有率分析,2020年及2027年(%)
  • 與前一年同期比較成長分析,2017-2027
  • 市場區隔趨勢
    • 冷凍乾燥
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)
    • 注射劑
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)

第7章 血漿蛋白分解酵素C1抑制劑治療市場:各流通管道,2016年∼2027年(百萬美元)

  • 簡介
  • 市場佔有率分析,2020年及2027年(%)
  • 與前一年同期比較成長分析,2017-2027
  • 市場區隔趨勢
    • 院內藥局
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)
    • 零售藥局
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)
    • 線上藥局
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率,2016年∼2027年,(百萬美元)

第8章 血漿蛋白分解酵素C1抑制劑治療市場:各地區,2016年-2027年(百萬美元)

  • 簡介
  • 市場佔有率分析:各國,2020年及2027年(%)
  • 與前一年同期比較成長分析,各國,2017-2027
  • 北美
  • 簡介
  • 市場規模與預測:各藥物類型,2016年∼2027年(百萬美元)
  • 市場規模與預測:各用量,2016年∼2027年(百萬美元)
  • 市場規模與預測:各流通管道,2016年∼2027年(百萬美元)
  • 市場規模與預測:各國,2016年∼2027年(百萬美元)
    • 美國
    • 加拿大
  • 南美
  • 簡介
  • 市場規模與預測:各藥物類型,2016年∼2027年(百萬美元)
  • 市場規模與預測:各用量,2016年∼2027年(百萬美元)
  • 市場規模與預測:各流通管道,2016年∼2027年(百萬美元)
  • 市場規模與預測:各國,2016年∼2027年(百萬美元)
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他
  • 歐洲
  • 簡介
  • 市場規模與預測:各藥物類型,2016年∼2027年(百萬美元)
  • 市場規模與預測:各用量,2016年∼2027年(百萬美元)
  • 市場規模與預測:各流通管道,2016年∼2027年(百萬美元)
  • 市場規模與預測:各國,2016年∼2027年(百萬美元)
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 亞太地區
  • 簡介
  • 市場規模與預測:各藥物類型,2016年∼2027年(百萬美元)
  • 市場規模與預測:各用量,2016年∼2027年(百萬美元)
  • 市場規模與預測:各流通管道,2016年∼2027年(百萬美元)
  • 市場規模與預測:各國,2016年∼2027年(百萬美元)
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 其他
  • 中東
  • 簡介
  • 市場規模與預測:各藥物類型,2016年∼2027年(百萬美元)
  • 市場規模與預測:各用量,2016年∼2027年(百萬美元)
  • 市場規模與預測:各流通管道,2016年∼2027年(百萬美元)
  • 市場規模與預測:各國,2016年∼2027年(百萬美元)
    • GCC
    • 以色列
    • 其他
  • 非洲
  • 簡介
  • 市場規模與預測:各藥物類型,2016年∼2027年(百萬美元)
  • 市場規模與預測:各用量,2016年∼2027年(百萬美元)
  • 市場規模與預測:各流通管道,2016年∼2027年(百萬美元)
  • 市場規模與預測:各國家/地區,2016年∼2027年(百萬美元)
    • 南非
    • 中非
    • 北非

第9章 競爭情形

  • 企業簡介
  • CSL Behring LLC.
  • 臨床試驗階段組合
  • 武田藥品工業株式會社
  • 臨床試驗階段組合
  • Ionis Pharmaceuticals, Inc.
  • 臨床試驗階段組合
  • Pharming Technologies B.V.
  • 臨床試驗階段組合
  • Centogene AG
  • 臨床試驗階段組合
  • BioCryst Pharmaceuticals
  • 臨床試驗階段組合
  • KalVista Pharmaceuticals,Inc。
  • 臨床試驗階段組合
目錄

Title:
Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.

Market Dynamics

Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.

Key features of the study:

  • This report provides in-depth analysis of the global plasma protease C1-inhibitor treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global plasma protease C1-inhibitor treatment market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protease C1-inhibitor treatment market.

Detailed Segmentation:

  • Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type:
    • C1-inhibitors
    • Kallikrein Inhibitor
    • Selective Bradykinin B2 Receptor Antagonist
  • Global Plasma Protease C1-inhibitor Treatment Market, By Dosage:
    • Lyophilized
    • Injectable
  • Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Plasma Protease C1-inhibitor Treatment Market, By Region:
    • North America
      • By Drug Type:
      • C1-inhibitors
      • Kallikrein Inhibitor
      • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
      • Lyophilized
      • Injectable
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Type:
      • C1-inhibitors
      • Kallikrein Inhibitor
      • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
      • Lyophilized
      • Injectable
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type:
      • C1-inhibitors
      • Kallikrein Inhibitor
      • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
      • Lyophilized
      • Injectable
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type:
      • C1-inhibitors
      • Kallikrein Inhibitor
      • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
      • Lyophilized
      • Injectable
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
      • C1-inhibitors
      • Kallikrein Inhibitor
      • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
      • Lyophilized
      • Injectable
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type:
      • C1-inhibitors
      • Kallikrein Inhibitor
      • Selective Bradykinin B2 Receptor Antagonist
      • By Dosage:
      • Lyophilized
      • Injectable
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles:
    • CSL Behring LLC *
      • Company Overview
      • Clinical Trial Phase Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Takeda Pharmaceutical Company Limited
    • Ionis Pharmaceuticals, Inc.
    • Pharming Technologies B.V.
    • Centogene AG
    • BioCryst Pharmaceuticals
    • KalVista Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Dosage
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Impact Analysis
  • Market Opportunities
  • Collaboration and acquisition

4. Plasma Protease C1-inhibitor Treatment Market - Impact of COVID-19 Pandemic

  • Post COVID-19 Impact
  • COVID-19 Impact on Research and Development Activities
  • Demand and Supply Analysis
  • Overall impact on manufacturing industry

5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • C1-inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Kallikrein Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Selective Bradykinin B2 Receptor Antagonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Lyophilized
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, By Country, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Dosage, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Dosage, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Dosage, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Dosage, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Dosage, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Drug Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Dosage, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2016-2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
  • CSL Behring LLC.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Takeda Pharmaceutical Company Limited
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Pharming Technologies B.V.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Centogene AG
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • BioCryst Pharmaceuticals
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • KalVista Pharmaceuticals, Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies

Browse 32 market data tables and 30 figures on " Plasma Protease C1-inhibitor Treatment Market - Global forecast to 2027".